Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (16776)	5/13/2005 8:56:22 PM
From: Ian@SI	Read Replies (2) \| Respond to of 52153

Think I've seen ALKS mentioned here before... +++++++++++++++++++ Alkermes' Potential Is Promising Alkermes Inc. (ALKS: Nasdaq) By WR Hambrecht ($11.72, May 12, 2005) WE ARE INITIATING COVERAGE of Alkermes with a Buy rating. We have a 12- to 18-month price target of $15, which is 33 times to our fiscal 2009 earnings-per-share estimate of 72 cents, discounted back at 25% per annum. We estimate revenue will grow from $76 million in fiscal 2005 to $332 million by fiscal 2009, with the first full year of profitability in fiscal 2008. We continue to believe Alkermes has significant long-term earnings potential, as the antipsychotic drug Risperdal Consta continues to post a strong performance. Also, Alkermes' product AIR Insulin, which targets a sizable potential inhaled insulin market, is advancing into late-stage development. -- Andrew Forman -- Wellington Chang